MétaCan
Menu
Back to cohort
Record W2562830036 · doi:10.1200/jco.2016.69.4182

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527

2017· article· en· W2562830036 on OpenAlexaff
Rachel A. Freedman, Jared C. Foster, Drew K. Seisler, Jacqueline M. Lafky, Hyman B. Muss, Harvey Jay Cohen, Jeanne S. Mandelblatt, Eric P. Winer, Clifford A. Hudis, Ann H. Partridge, Lisa A. Carey, Constance Cirrincione, Alvaro Moreno‐Aspitia, Gretchen Kimmick, Aminah Jatoi, Arti Hurria

Bibliographic record

VenueJournal of Clinical Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicEthics in Clinical Research
Canadian institutionsPediatric Oncology Group
FundersNational Cancer Institute
KeywordsMedicineBreast cancerInternal medicineClinical trialAccrualOdds ratioAdjuvant therapyOncologyHormonal therapyRandomized controlled trialCancer

Abstract

fetched live from OpenAlex

Purpose Despite increasing awareness of accrual challenges, it is unknown if accrual of older patients to breast cancer treatment trials is improving. Methods We examined accrual of older patients to Alliance for Clinical Trials in Oncology systemic therapy breast cancer trials during 1985-2012 and compared disease characteristics and reasons for therapy cessation for older (age ≥ 65 years and ≥ 70 years) versus younger (age < 65 years and < 70 years) participants. To examine accrual trends, we modeled age as a function of time, using logistic regression. Results Overall, 17% of study participants were ≥ 65 years of age. Approximately 15%, 24%, and 24% of participants in adjuvant, neoadjuvant, and metastatic trials were age ≥ 65 years, and 7%, 15%, and 13% were age ≥ 70 years, respectively. The odds of a patient age ≥ 65 years enrolling significantly increased over time for adjuvant trials (odds ratio [OR] per year, 1.04; 95% CI, 1.04 to 1.05) but decreased significantly for neoadjuvant and metastatic trials (OR, 0.62; 95% CI, 0.58 to 0.67 and OR, 0.98, 95% CI, 0.97 to 1.00). Similar trends were seen for those age ≥ 70 years but these were statistically significant for adjuvant and neoadjuvant trials only (OR, 1.05, 95% CI, 1.04 to 1.07; and OR, 0.57, 95% CI, 0.52 to 0.62). In general, those age ≥ 65 years ( v those < 65 years) in adjuvant studies had a higher mean number of lymph nodes involved and more hormone receptor-negative tumors, although tumor sizes were similar. Early protocol treatment cessation was also more frequent in those age ≥ 65 years (50%) versus < 65 years (35.9%) across trials. Conclusion Older patients with breast cancer remain largely underrepresented in cooperative group therapeutic trials. We observed some improvement in accrual to adjuvant trials but worsening of accrual for neoadjuvant/metastatic trials. Novel strategies to increase accrual of older patients are critical to meaningfully change the evidence base for this growing patient population.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.134
metaresearch head score (Gemma)0.152
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.866
Threshold uncertainty score0.706

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1340.152
Meta-epidemiology (narrow)0.0020.002
Meta-epidemiology (broad)0.0020.004
Bibliometrics0.0030.005
Science and technology studies0.0030.002
Scholarly communication0.0040.004
Open science0.0030.004
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0360.016

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.635
GPT teacher head0.712
Teacher spread0.077 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
DomainMethods
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations93
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicEthics in Clinical ResearchFrench-language works237,207